NEW YORK (GenomeWeb) – Cenix BioScience this week announced it has signed an agreement to provide target-validation services to BASF company Metanomics.
NEW YORK (GenomeWeb) – Cenix Biosciences this week announced that it has signed an agreement to provide RNAi-based high-content screening services to Germany's Bayer Pharma.
Cenix BioScience this week announced that it has signed an agreement to provide its research services to Swiss drugmaker Debiopharm.
Cenix BioScience said this week that its roughly one-year old service contract with Ugichem, a developer of novel gene-silencing therapeutics, has been extended.
The company has added respiratory and inflammation to an RNAi screening program that began with oncology.
The company, which until recently has focused almost exclusively "on cell-based work," expects that the delivery technology will facilitate its in vivo work and enable RNAi-based therapeutics.
The company will use RNAi technologies for cell-based screens for cancer drugs.
Vivek Murthy is no longer the surgeon general of the US, the Associated Press reports.
People around the globe took to the streets to support science — some with signs.
Parents who learn of their increased genetic risk of disease also contend with telling their children about theirs, the New York Times writes.
In PLOS this week: loci linked to body mass index measurements, long non-coding RNA expression and urothelial carcinoma prognosis, and more.